# BlossomHill Therapeutics, Inc. — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_c4a796de13adafed80fe · retrieved 2026-08-11T16:02:23.825Z

## Overview
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop innovative small-molecule medicines for cancer treatment, with two clinical-stage programs (BH-30643, an OMNI-EGFR inhibitor for EGFR-mutant NSCLC, and BH-30236, a CLK inhibitor for R/R AML and HR-MDS) and one preclinical-stage candidate (BH-501284, a pan-KRAS inhibitor).

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company developing small-molecule cancer therapies, is conducting an initial public offering of 7,812,500 shares of common stock at an expected price range of $15.00 to $17.00 per share. The company has also granted underwriters an option to purchase up to 1,171,875 additional shares within 30 days. BlossomHill has applied to list its common stock on The Nasdaq Global Select Market under the symbol "BLSM," and the offering is contingent upon obtaining such approval. At the midpoint price of $16.00 per share, the company estimates net proceeds of approximately $111.7 million (or $129.1 million if the underwriter option is exercised in full), after deducting underwriting discounts and estimated offering expenses.

## Terms
- Counterparty: J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, H.C. Wainwright & Co. · Consideration: cash · Price/share: $16

## Key dates
- Announced 2026-08-03

## Timeline
- 2026-08-03 · S-1/A (0001193125-26-329416): S-1/A - BlossomHill Therapeutics, Inc. — *BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop innovative small-molecule medicines for cancer treatment, with two clinical-stage programs (BH-30643, an OMNI-EGFR inhibitor for EGFR-mutant NSCLC, and BH-30236, a CLK inhibitor for R/R AML and HR-MDS) and one preclinical-stage candidate (BH-501284, a pan-KRAS inhibitor).* BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company developing small-molecule cancer therapies, is conducting an initial public offering of 7,812,500 shares of common stock at an expected price range of $15.00 to $17.00 per share. The company has also granted underwriters an option to purchase up to 1,171,875 additional shares within 30 days. BlossomHill has applied to list its common stock on The Nasdaq Global Select Market under the symbol "BLSM," and the offering is contingent upon obtaining such approval. At the midpoint price of $16.00 per share, the company estimates net proceeds of approximately $111.7 million (or $129.1 million if the underwriter option is exercised in full), after deducting underwriting discounts and estimated offering expenses.
  https://www.sec.gov/Archives/edgar/data/1839970/0001193125-26-329416.txt

## Citations
- 0001193125-26-329416 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526329416